Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Zymedi General Information
Developing ZMA001 mAb targeting KARS1 for PAH and PH-ILD in pre-clinical stage. Also has ZMC001 SM for NASH and ZMC101 SM for colorectal and lung cancer in early development stages.
Contact Information
Drug Pipeline
ZMA001
Phase 1Key Partnerships
Evotec SE, Yonsei University
Zymedi Funding
No funding data available
To view Zymedi's complete valuation and funding history, request access »